The chemical structure of probucol differs from that of other hypolipemic agents, and its mechanism of action is unknown. This agent lowers elevated serum cholesterol (and low-density lipoprotein) levels and appears to be effective when used as an adjunct to a low-cholesterol, low-saturated-fat diet for treatment of type lla hyperlipoproteinemia in adults; however, it is less effective than cholestyramine resin in patients with familial type lla disorder. Although probucol has no consistent effect on elevated triglyceride levels, it may be useful as an adjunct to other drugs that lower these concentrations in patients with types llb, III, and IV hyperlipoproteinemia when hypercholesterolemia persists. Probucol is generally well tolerated.
(JAMA 238:2537-2538, 1977)
Murphy BF. Probucol (Lorelco) in Treatment of Hyperlipemia. JAMA. 1977;238(23):2537–2538. doi:10.1001/jama.1977.03280240083035
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: